Next 10 |
home / stock / rvmd / rvmd articles
As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in t...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Shares of Helen of Troy Limited (NASDAQ:HELE) fell sharply during Tuesday's session after the company reported soft first-quarter earnings and...
REDWOOD CITY, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing t...
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a clinical-stage oncology company developing ta...
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in ...
Shares of Ascent Solar Technologies, Inc. (NASDAQ: ASTI) fell sharply during Wednesday’s session after the company announced pricing of a $6...
Revolution Medicines, Inc. (NASDAQ:RVMD) shares are trading higher Wednesday. The company announced the publication of several peer-reviewed ...
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday. Shares of Roblox Corporation (NYSE: RBLX) rose during Wedne...
News, Short Squeeze, Breakout and More Instantly...
Revolution Medicines Inc. Company Name:
RVMD Stock Symbol:
NASDAQ Market:
Revolution Medicines Inc. Website:
2024-07-24 09:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-14 06:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Re...